Get the Stockscreener App
46.58
0.66%
-0.31
Pre-market:
46.50
-0.08
-0.17%
Tarsus Pharmaceuticals Inc stock is traded at $46.58, with a volume of 349.43K.
It is down -0.66% in the last 24 hours and up +27.20% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$46.89
Open:
$46.9
24h Volume:
349.43K
Relative Volume:
0.50
Market Cap:
$1.78B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-13.78
EPS:
-3.38
Net Cash Flow:
$-123.00M
1W Performance:
+0.16%
1M Performance:
+27.20%
6M Performance:
+20.27%
1Y Performance:
+166.17%
1-Day Range:
$45.73
$47.37
1-Week Range:
$43.25
$52.99
52-Week Range:
$15.60
$52.99
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| TARS | 46.58 | 1.78B | 17.39M | -135.89M | -123.00M | -3.38 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade - Yahoo Finance
22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP - MarketBeat
What is Lifesci Capital's Forecast for TARS FY2024 Earnings? - MarketBeat
Tarsus Pharmaceuticals Appoints Kate Goodrich, MD, to its Board of Directors - Vision Monday
US$65.33That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results - Simply Wall St
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.3%Here's What Happened - MarketBeat
Midday Stock Roundup: Viant Tech Up Since Q3 Earnings - Orange County Business Journal
Trend Tracker for (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales By Investing.com - Investing.com UK
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharma - GuruFocus.com
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharm - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year High After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $52 - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $52 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Tarsus Pharmaceuticals Reports Strong Q3 2024 Performance - TipRanks
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings: EPS of $(0.6 - GuruFocus.com
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements - GlobeNewswire
Tarsus Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors - The Manila Times
Tarsus Pharma Strengthens Board with Humana CMO Dr. Kate Goodrich Appointment | TARS Stock News - StockTitan
Jennison Associates LLC Increases Stake in Tarsus Pharmaceuticals Inc - GuruFocus.com
Tarsus Pharmaceuticals Appoints Elizabeth Yeu, MD, as Chief Medical Officer - Vision Monday
Lisanti Capital Growth LLC Takes $1.31 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled - MSN
Creative Planning Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesday - MarketBeat
Creative Planning Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - GlobeNewswire
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 - Investing.com
Tarsus Pharmaceuticals stock hits 52-week high at $48.65 By Investing.com - Investing.com UK
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - GlobeNewswire
Tarsus Pharmaceuticals appoints new Chief Medical Officer - Investing.com India
Tarsus Pharmaceuticals appoints new Chief Medical Officer By Investing.com - Investing.com South Africa
Papulopustular Rosacea Market to Expand Significantly by 2034, States DelveInsight Report | Sol-Gel Technologies, Galderma, CollaGenex Pharma, Tarsus Pharma, Pfizer - Barchart
Papulopustular Rosacea Market to Expand Significantly by 2034, - openPR
Tarsus Pharma Names Leading Ophthalmologist Dr. Elizabeth Yeu as New Chief Medical Officer | TARS Stock News - StockTitan
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Tarsus Pharmaceuti - GuruFocus.com
Emerald Advisers LLC Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 8.5% HigherShould You Buy? - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):